IL193639A - Purified collagen for use as a cellulite treatment drug - Google Patents

Purified collagen for use as a cellulite treatment drug

Info

Publication number
IL193639A
IL193639A IL193639A IL19363908A IL193639A IL 193639 A IL193639 A IL 193639A IL 193639 A IL193639 A IL 193639A IL 19363908 A IL19363908 A IL 19363908A IL 193639 A IL193639 A IL 193639A
Authority
IL
Israel
Prior art keywords
medicament
purified
couagenase
treating cellulite
purified collagenase
Prior art date
Application number
IL193639A
Other languages
English (en)
Hebrew (he)
Other versions
IL193639A0 (en
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of IL193639A0 publication Critical patent/IL193639A0/en
Publication of IL193639A publication Critical patent/IL193639A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
IL193639A 2006-02-22 2008-08-21 Purified collagen for use as a cellulite treatment drug IL193639A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77569006P 2006-02-22 2006-02-22
US11/703,269 US20070224184A1 (en) 2006-02-22 2007-02-07 Method for treating cellulite
PCT/US2007/004752 WO2007100675A2 (en) 2006-02-22 2007-02-22 Collagenase for treating cellulite

Publications (2)

Publication Number Publication Date
IL193639A0 IL193639A0 (en) 2011-08-01
IL193639A true IL193639A (en) 2015-01-29

Family

ID=38325147

Family Applications (1)

Application Number Title Priority Date Filing Date
IL193639A IL193639A (en) 2006-02-22 2008-08-21 Purified collagen for use as a cellulite treatment drug

Country Status (19)

Country Link
US (4) US20070224184A1 (OSRAM)
EP (1) EP1991258B1 (OSRAM)
JP (5) JP5775658B2 (OSRAM)
KR (2) KR20120006063A (OSRAM)
AU (1) AU2007221225B2 (OSRAM)
BR (1) BRPI0708186A2 (OSRAM)
CA (1) CA2643171C (OSRAM)
DK (1) DK1991258T3 (OSRAM)
ES (1) ES2553184T3 (OSRAM)
HR (1) HRP20151182T1 (OSRAM)
HU (1) HUE025918T2 (OSRAM)
IL (1) IL193639A (OSRAM)
MX (1) MX2008010767A (OSRAM)
NZ (1) NZ570642A (OSRAM)
PL (1) PL1991258T3 (OSRAM)
PT (1) PT1991258E (OSRAM)
RS (1) RS54372B1 (OSRAM)
SI (1) SI1991258T1 (OSRAM)
WO (1) WO2007100675A2 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
KR20090130158A (ko) * 2005-01-21 2009-12-17 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 유착 관절낭염을 치료하는 방법
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US20090233885A1 (en) * 2006-07-14 2009-09-17 Duncan Diane I Compositions and Methods for Fat Reduction
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
WO2010102262A1 (en) 2009-03-06 2010-09-10 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
JP5284239B2 (ja) * 2009-10-07 2013-09-11 株式会社メタコ スクリーン装置
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
EP3581199B1 (en) * 2011-10-21 2023-05-31 Endo Global Ventures Methods of treatment or reduction of edematous-fibrosclerotic panniculopathy
CA2861033C (en) 2012-01-12 2017-07-25 Auxilium International Holdings, Inc. Clostridium histolyticum enzymes and methods for the use thereof
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
WO2014107745A1 (en) 2013-01-07 2014-07-10 Halozyme, Inc. Metal sensitive mutants of matrix metalloproteases and uses thereof
EP2968484B1 (en) 2013-03-15 2020-11-25 BioSpecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
US10117892B2 (en) 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
KR20230003601A (ko) * 2017-03-01 2023-01-06 엔도 벤쳐즈 리미티드 셀룰라이트를 평가하고 치료하기 위한 장치 및 방법
CN118325876A (zh) 2017-03-28 2024-07-12 恩多风投有限公司 生产胶原酶的改进方法
WO2020021332A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
KR20210079291A (ko) * 2018-09-18 2021-06-29 엔도 글로벌 에스테틱스 리미티드 셀룰라이트를 치료하기 위한 조성물 및 방법
US20220305094A1 (en) 2019-01-06 2022-09-29 Endo Global Aesthetics Limited Collagenase formulations and methods of producing the same
EP4045078A1 (en) 2019-10-15 2022-08-24 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
BR112022010042A2 (pt) * 2019-11-26 2022-08-16 Standard Of Care Corp Composições de hialuronidase e métodos de uso da mesma para tratar celulite
IL316852A (en) * 2022-05-10 2025-01-01 Endo Global Aesthetics Ltd Methods for reducing collagenase-mediated bruising in a subject with cellulite

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338300A (en) * 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
JP3028852B2 (ja) * 1994-06-24 2000-04-04 ロシュ ダイアグノスティックス コーポレーション ヒストリチクス菌から得られるコラゲナーゼおよび２つの他のプロテアーゼの精製混合物
US5589171A (en) * 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) * 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
TR200001789T2 (tr) * 1997-10-03 2000-10-23 Lavipharm Laboratories, Inc. Prolamin-bitki kutuplu lipit kompozisyonu, bunun hazırlama ve uygulama metodu
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
US6358539B1 (en) * 1999-08-20 2002-03-19 Howard Murad Pharmaceutical compositions for reducing the appearance of cellulite
KR20090130158A (ko) * 2005-01-21 2009-12-17 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 유착 관절낭염을 치료하는 방법
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
US20210169844A1 (en) * 2019-12-10 2021-06-10 Tulex Pharmaceuticals Inc. Compositions and methods for treating epilepsy, seizures and other conditions

Also Published As

Publication number Publication date
US20190053995A1 (en) 2019-02-21
NZ570642A (en) 2012-03-30
JP2018199733A (ja) 2018-12-20
EP1991258B1 (en) 2015-08-12
US20070224184A1 (en) 2007-09-27
JP2016204396A (ja) 2016-12-08
RS54372B1 (sr) 2016-04-28
JP6649449B2 (ja) 2020-02-19
JP5775658B2 (ja) 2015-09-09
HRP20151182T1 (hr) 2016-01-01
WO2007100675A2 (en) 2007-09-07
US10123959B2 (en) 2018-11-13
IL193639A0 (en) 2011-08-01
JP2020015771A (ja) 2020-01-30
EP1991258A2 (en) 2008-11-19
AU2007221225B2 (en) 2010-02-11
JP6498167B2 (ja) 2019-04-10
JP2009527570A (ja) 2009-07-30
US20160279046A1 (en) 2016-09-29
CA2643171C (en) 2018-10-02
MX2008010767A (es) 2008-09-01
JP6853331B2 (ja) 2021-03-31
WO2007100675A3 (en) 2007-11-15
KR20080108996A (ko) 2008-12-16
PL1991258T3 (pl) 2016-04-29
US20220249348A1 (en) 2022-08-11
BRPI0708186A2 (pt) 2011-05-24
AU2007221225A1 (en) 2007-09-07
ES2553184T3 (es) 2015-12-04
DK1991258T3 (en) 2015-11-16
HUE025918T2 (en) 2016-05-30
JP2015134840A (ja) 2015-07-27
KR20120006063A (ko) 2012-01-17
PT1991258E (pt) 2015-11-24
CA2643171A1 (en) 2007-09-07
SI1991258T1 (sl) 2016-02-29

Similar Documents

Publication Publication Date Title
IL193639A (en) Purified collagen for use as a cellulite treatment drug
MX337511B (es) Medicamentos y metodos para tratar cefaleas.
WO2007081975A3 (en) Method of treating multiple sclerosis
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
JP2018199733A5 (OSRAM)
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
WO2009129531A3 (en) Bupivacaine formulation in a polyorthoester carrier
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
WO2009129527A3 (en) Baclofen formulation in a polyorthoester carrier
WO2007143607A3 (en) Method of treating atrophic vaginitis
WO2008036682A3 (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
NO20023473D0 (no) Sammensetninger for levering av en kortisol antagonist
MX392388B (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe)
ATE476981T1 (de) Zusammensetzungen zur bekämpfung von beta- lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
PH12015501373A1 (en) Injectable depot formulation comprising optically active tolvaptan and process of producing the same
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2007100590A3 (en) Methods for treating cellulite
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
WO2007087154A3 (en) Methods for enhancing therapeutic effects of a neurotoxin
WO2006078870A3 (en) Methods for treating adhesive capsulitis
WO2008114376A1 (ja) メラニン生成抑制組成物
Kim et al. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed